{"schema_version":"1.0","type":"article","title":"Biotech IR Is Not Making Slides Prettier; It Is Turning Pipelines Into Trackable Capital-Market Stories","url":"https://drugnews.com.tw/articles/2026-06-10-biotech-ir-capital-market-story-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-10-biotech-ir-capital-market-story-en.md","lang":"en","date":"2026-06-10","publish_at":"2026-06-10T10:30:00+08:00","updated_at":"2026-06-10","category":"商業分析系列","topic":"IR 與資本市場","tags":["IR and Capital Markets","Capital markets","Biotech business analysis","Drug development"],"summary":"Biotech IR is not cosmetic storytelling. Good IR turns clinical, CMC, regulatory, commercial, and financing milestones into a capital-market narrative that investors can actually track.","key_points":[],"facts":[],"sections":["Core Thesis","Why It Matters","Reading Framework","What To Watch Next","Original Chinese Edition"],"references":[],"images":[],"cover_image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-10）。Biotech IR Is Not Making Slides Prettier; It Is Turning Pipelines Into Trackable Capital-Market Stories。https://drugnews.com.tw/articles/2026-06-10-biotech-ir-capital-market-story-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-06-10-biotech-ir-capital-market-story.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}